Title |
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma
|
---|---|
Published in |
Clinical Sarcoma Research, April 2015
|
DOI | 10.1186/s13569-014-0018-3 |
Pubmed ID | |
Authors |
Olivia Bally, Louis Tassy, Bertrand Richioud, Anne-Valérie Decouvelaere, Jean-Yves Blay, Olfa Derbel |
Abstract |
Epithelioid hemangioendothelioma is a rare connective tissue tumor of vascular origin. It is most commonly found in young to middle aged women, and its clinical behavior is remakably variable from an indolent metastatic tumor to an aggressive rapidly growing neoplasm. Most tumors are diagnosed in an advanced unresectable phase and when clinically aggressive, require systemic cytotoxic treatment of sarcoma. Then, the 5-year survival rate after chemotherapy does not exceed 30%. Antiangiogenics are active in selected sarcoma subtypes: pazopanib, the only anti angiogenic registered agent for sarcoma provides a median PFS of 4.5 months only in the pivotal study. Their activity in EHE has been reported but long term outcome of these patients remain unreported. We report a case of a female patient with HEH who was treated with pazopanib for almost 8 years. Pazopanib therapy resulted in clinical improvement of symptoms and durable stabilization of liver tumors and lung lesions. Pazopanib is a promising therapeutic option in patients with HEH. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 31% |
Student > Postgraduate | 3 | 19% |
Other | 2 | 13% |
Student > Doctoral Student | 1 | 6% |
Researcher | 1 | 6% |
Other | 1 | 6% |
Unknown | 3 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 44% |
Biochemistry, Genetics and Molecular Biology | 2 | 13% |
Social Sciences | 1 | 6% |
Immunology and Microbiology | 1 | 6% |
Unknown | 5 | 31% |